Clinical Trials · NCT02863328
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 822
- Start date
- Aug 2016
- Locations
- 106 sites, 12 countries
- Primary endpoint
- Change in HbA1c